Germany Approves EU’s First Psilocybin Access Program

Germany has become the first EU country to approve a compassionate access program for psilocybin, allowing limited use for patients with treatment-resistant depression. Filament will supply the program with its botanical psilocybin drug candidate, PEX010; the treatment will be administered on an inpatient basis at two clinics in Germany, paired with psychotherapy.